AUSTRALIAN PRODUCT INFORMATION – COMIRNATY …
• Each dose must contain 0.3 mL of vaccine. • If the amount of vaccine remaining in the vial cannot provide a full dose of 0.3 mL, discard the vial and any excess volume. • Do not pool excess vaccine from multiple vials. The preferred site of …
Tags:
Information, Product, Vaccine, Product information
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document:
Advertisement
Documents from same domain
AUSTRALIAN PRODUCT INFORMATION (ChAdOx1-S) …
www.tga.gov.auAUSTRALIAN PRODUCT INFORMATION COVID-19 Vaccine AstraZeneca (ChAdOx1-S) solution for injection . 1 NAME OF THE MEDICINE . ChAdOx1-S (provisional ABN) 2 QUALITATIVE AND QUANTITATIVE COMPOSITION . Each multi-dose vial contains 5x10. 11. viral particles (vp) of (ChAdOx1-S . a, b) in 5 mL. One dose (0.5 mL) contains 5x10. 10. vp of …
Information, Product, Name, Product information, Qualitative, Astrazeneca
COMIRNATY™ COVID-19 VACCINE
www.tga.gov.auDo not receive this vaccine if you are allergic to any of these ingredients. What COMIRNATY looks like COMIRNATY is a white to off-white suspension provided in a multidose clear glass vial. After dilution, each vial contains 6 doses of vaccine. AUST R 346290. Who distributes COMIRNATY Pfizer Australia Pty Ltd Sydney NSW www.pfizer.com.au
Australian Public Assessment Report for Silodosin
www.tga.gov.auAustralian Public Assessment Report for Silodosin Proprietary Product Name: Urorec ... • To report a problem with a medicine or medical device, please see the information on ... //www.tga.gov.au>. About AusPARs • An Australian Public Assessment Re port (AusPAR) provides information about the evaluation of a prescription medicine and the ...
Assessment, Report, Public, Australian, Ports, Australian public assessment report for silodosin, Silodosin, Public assessment re port
Australian public assessment report for Linagliptin
www.tga.gov.au• An Australian Public Assessment Record (AusPAR) provides information about the evaluation of a prescription medicine and the considerations that led the TGA to approve or not approve a prescription medicine submission.
Assessment, Report, Public, Australian, Public assessment, Australian public assessment report for linagliptin, Linagliptin
Australian public assessment report for BNT162b2 (mRNA)
www.tga.gov.auThe RNA is encapsulated in lipid nanoparticles (LNPs), which enables entry into host cells, expression of the S protein, and elicitation of both antibody and cellular immune responses. The vaccine is supplied as a white to off white sterile frozen liquid, packaged in a multi dose clear glass 2 mL vial with a rubber stopper,
Guideline for the labelling of medicines
www.tga.gov.auGuideline for the labelling medicines of istorical consultation document Draft - Version 1.0, August 2014
Guidance 18: Impurities in drug substances and …
www.tga.gov.auTherapeutic Goods Administration Guidance 18: Impurities in drug substances and drug products V1.0 August 2013 Page 3 of 13 Version history Version Description of change Author Effective date
Drug, Impurities, Substance, Impurities in drug substances and, Impurities in drug substances and drug
Explanatory notes for pharmaceutical manufacturers on the ...
www.tga.gov.auPE 008-4 3 of 8 1 January 2011 4. SCOPE These Explanatory Notes apply to the preparation and content of the Site Master File. Manufacturers should refer to regional / …
Notes, Pharmaceutical, Life, Manufacturers, Explanatory notes, Explanatory, Explanatory notes for pharmaceutical manufacturers
The use of GMDN codes for IVD medical devices in Australia
www.tga.gov.auGlobal Medical Device Nomenclature (GMDN) The GMDN is an international nomenclature system used by regional or national regulatory bodies to consistently describe medical devices: 1 • consistent assessment of devices before they are approved for supply . GMDN codes are used to
Devices, Medical, Global, Nomenclature, Global medical device nomenclature
COVID-19 rapid antigen self-tests
www.tga.gov.auCOVID-19 rapid antigen self-tests. This guidance refe rs to COVID -19 (caused by SARS-CoV-2) only and does not include self-tests to detect other types of coronavirus , or COVID_19 rapid antibody tests . COVID-19 rapid antigen self-tests are tests that allow individuals to collect a specimen, conduct a test and interpret the results by themselves.
Related documents
Many vaccine information statements are Varicella ...
www.cdc.govVaccine Information Statement 4. Risks of a vaccine reaction Sore arm from the injection, redness or rash where the shot is given, or fever can happen after varicella vaccination. More serious reactions happen very rarely. These can include pneumonia, infection of the brain and/
Vaccine Information Statement: Recombinant Zoster ...
www.immunize.orgOct 30, 2019 · recombinant shingles vaccine also protects against PHN. Recombinant shingles vaccine is the preferred vaccine for the prevention of shingles. However, a different vaccine, live shingles vaccine, may be used in some circumstances. The recombinant shingles vaccine is recommended for adults 50 years and older without serious immune problems.
Vaccine ingredients and allergy information
coronavirus.delaware.govMay 13, 2021 · Vaccine ingredients and allergy information You have had a severe or immediate1 allergic reaction after a previous dose of this vaccine or to any ingredient of this vaccine, particularly polysorbate 80 or polyethylene glycol (PEG) •If polysorbate 80 allergy, do not take J&J vaccine; discuss with medical provider if you should get Pfizer or ...